Back when we started PCF in 1993, the outlook for prostate cancer patients was bleak. Despite its common occurrence, prostate cancer was still the “hidden” cancer. It received little attention from researchers. Government and private sources invested little in finding a cure.
PCF saw it differently. We saw a cancer that was second only to skin cancer in the frequency of its occurrence in the U.S. We saw a disease that would strike 1 in 9 U.S. men—taking more than 29,000 lives each year. We saw treatments that sometimes left men incontinent, impotent and depressed—damaging quality of life for them and their loved ones.
PCF was founded to give men and their families hope. We set out to harness more resources—both financial and human—to accelerate the development of new breakthroughs and find a cure as quickly as possible.
We’ve made considerable progress. Today we’re the #1 philanthropic organization funding prostate cancer research globally. We’ve helped change how people view the disease—especially those in medical research. Some of the world’s most talented and dedicated investigators now use PCF grants to unlock the mysteries of prostate cancer and bring new treatments to patients.
Perhaps most significantly, when PCF first started, only seven FDA-approved drugs were available for use in the treatment of prostate cancer. Through PCF support, that number has grown to 13—and many more treatments are in the pipeline.
Still, because of limited funds, PCF must turn down dozens of grant requests each year. While much progress has been made and the death rate has been reduced, we have yet to realize our goal of finding a cure. And the clock is ticking. That’s why we need your help now more than ever.
By making a donation, you’ll help spark new advancements that improve health and increase hope.
Every day, every dollar, every research project brings us closer to a world with no death from prostate cancer.
Please give to PCF and help us take the next steps.
Jonathan W. Simons, MD
President and Chief Executive Officer
David H. Koch Chair